Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M

Guardant Health, Inc.

2024-Q3 EPS reported -$2.66 revenue$537,202,000

Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).
Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.
Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.
Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.
Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.